Literature DB >> 9818077

Primary cervical malignant teratoma with a rib metastasis in an adult: five-year survival after surgery and chemotherapy. A case report with a review of the literature.

C Als1, H Laeng, T Cerny, J A Kinser, H Rösler, R Häusler.   

Abstract

We report a case of a man presenting with a cervical malignant teratoma and a chondrosarcomatous rib metastasis. He was alive and free of recurrence five years and 10 months (= 70 months) after resection of the primary mass, followed by chemotherapy and subsequent resection of the rib tumor. This is the 35th patient reported in the literature and the first description in which an 'adjuvant' or primary chemotherapy was used. Previous patients with a cervical malignant teratoma, reported after lethal outcome, had survivals of one to 22 months (median nine months). In all patients with a preoperative clinical impression of an aggressive, differentiated or undifferentiated malignancy, the definite diagnosis of teratoma could only be made histologically. By analogy to germ cell tumors, the prognosis of malignant teratoma might be improved if complete excision is combined with new, adjuvant chemotherapy protocols for germ cell tumors. Lessons learned from this case are placed in the context of germ cell tumors in general and of non-gonadal malignant teratomas in particular.

Entities:  

Mesh:

Year:  1998        PMID: 9818077     DOI: 10.1023/a:1008277227111

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  2 in total

1.  Primary malignant teratoma with a primitive neuroectodermal tumor component in thyroid gland: a case report.

Authors:  Eunyoung Kim; Tae Seok Bae; Youngmee Kwon; Tae Hyun Kim; Ki-Wook Chung; Sun Wook Kim; Jungsil Ro; Eun Sook Lee
Journal:  J Korean Med Sci       Date:  2007-06       Impact factor: 2.153

2.  Malignant thyroid teratoma: report of an aggressive tumor in a 64-year-old man.

Authors:  R Vilallonga; C Zafon; C Ruiz-Marcellan; G Obiols; J M Fort; J A Baena; B Villanueva; A Garcia; M Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2013-09       Impact factor: 3.943

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.